Title
Category
Credits
Event date
Cost
  • Biopsychosocial
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 APA
  • 1.00 ASWB-ACE
  • 1.00 Contact Hours/ Participation
$0.00
In the last two decades, psychedelics have re-emerged as promising novel agents for treatment of a broad range of mental health conditions including depression, PTSD, substance use disorders, end-of-life anxieties, eating disorders, and more. Our understanding of their putative mechanisms of action has significantly evolved as well. Several Phase II and III clinical trials of psychedelic-assisted therapy (PAT) using psilocybin and MDMA are either complete or nearing completion, with some of these therapies projected to receive FDA approval within the next couple of years.
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 APA
  • 1.50 ASWB-ACE
  • 1.50 Contact Hours/ Participation
$0.00
In 2021, US Surgeon General Dr. Vivek Murthy described experiences of loneliness as “a dark thread through our nation’s most pressing public health challenges” (Murthy, 2021, Public Health Reports, 136[6]). Rates of loneliness across the globe have increased across age and demographic groups steadily over the past two decades, despite concomitant changes in communication technology and virtual interconnectedness.

Pages